Modality
mAb
MOA
PRMT5i
Target
PLK4
Pathway
Checkpoint
MGPsoriasis
Development Pipeline
Preclinical
Jan 2017
→ Nov 2029
PreclinicalCurrent
NCT07446549
727 pts·Psoriasis
2017-01→TBD·Not yet recruiting
NCT04613428
2,541 pts·MG
2023-01→2029-11·Recruiting
3,268 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-053.6y awayInterim· MG
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Not yet…
Preclinical
Recruit…
Catalysts
Interim
2029-11-05 · 3.6y away
MG
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07446549 | Preclinical | Psoriasis | Not yet recr... | 727 | ORR |
| NCT04613428 | Preclinical | MG | Recruiting | 2541 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 |